BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vogel J, Lin L, Litzky LA, Berman AT, Simone CB 2nd. Predicted Rate of Secondary Malignancies Following Adjuvant Proton Versus Photon Radiation Therapy for Thymoma. Int J Radiat Oncol Biol Phys. 2017;99:427-433. [PMID: 28871993 DOI: 10.1016/j.ijrobp.2017.04.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Santos PMG, Barsky AR, Hwang WT, Deville C, Wang X, Both S, Bekelman JE, Christodouleas JP, Vapiwala N. Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting. Cancer 2019;125:4278-93. [PMID: 31503338 DOI: 10.1002/cncr.32457] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
2 Zhou Q, Ke X, Man J, Zhang B, Wang F, Zhou J. Predicting Masaoka-Koga Clinical Stage of Thymic Epithelial Tumors Using Preoperative Spectral Computed Tomography Imaging. Front Oncol 2021;11:631649. [PMID: 33842338 DOI: 10.3389/fonc.2021.631649] [Reference Citation Analysis]
3 Rico M, Flamarique S, Casares C, García T, López M, Martínez M, Serrano J, Blanco M, Hernanz R, de Ingunza-Barón L, Marcos FJ, Couñago F. GOECP/SEOR radiotherapy guidelines for thymic epithelial tumours. World J Clin Oncol 2021; 12(4): 195-216 [PMID: 33959475 DOI: 10.5306/wjco.v12.i4.195] [Reference Citation Analysis]
4 Haefner MF, Verma V, Bougatf N, Mielke T, Tonndorf-Martini E, König L, Rwigema JM, Simone CB 2nd, Uhlmann L, Eichhorn F, Winter H, Grosch H, Haberer T, Herfarth K, Debus J, Rieken S. Dosimetric comparison of advanced radiotherapy approaches using photon techniques and particle therapy in the postoperative management of thymoma. Acta Oncol 2018;57:1713-20. [PMID: 30264630 DOI: 10.1080/0284186X.2018.1502467] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
5 Zhou J, Yang X, Chang CW, Tian S, Wang T, Lin L, Wang Y, Janopaul-Naylor JR, Patel P, Demoor JD, Bohannon D, Stanforth A, Eaton B, McDonald MW, Liu T, Patel SA. Dosimetric Uncertainties in Dominant Intraprostatic Lesion Simultaneous Boost Using Intensity Modulated Proton Therapy. Adv Radiat Oncol 2022;7:100826. [PMID: 34805623 DOI: 10.1016/j.adro.2021.100826] [Reference Citation Analysis]
6 Lideståhl A, Johansson G, Siegbahn A, Lind PA. Estimated Risk of Radiation-Induced Cancer after Thymoma Treatments with Proton- or X-ray Beams. Cancers (Basel) 2021;13:5153. [PMID: 34680302 DOI: 10.3390/cancers13205153] [Reference Citation Analysis]
7 Patel NV, Yu NY, Koroulakis A, Diwanji T, Sawant A, Sio TT, Mohindra P. Proton therapy for thoracic malignancies: a review of oncologic outcomes. Expert Rev Anticancer Ther 2021;21:177-91. [PMID: 33118427 DOI: 10.1080/14737140.2021.1844567] [Reference Citation Analysis]
8 Sun T, Lin X, Tong Y, Liu X, Pan L, Tao C, Duan J, Yin Y. Heart and Cardiac Substructure Dose Sparing in Synchronous Bilateral Breast Radiotherapy: A Dosimetric Study of Proton and Photon Radiation Therapy. Front Oncol 2019;9:1456. [PMID: 31998635 DOI: 10.3389/fonc.2019.01456] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
9 Loap P, Vitolo V, Barcellini A, De Marzi L, Mirandola A, Fiore MR, Vischioni B, Jereczek-Fossa BA, Girard N, Kirova Y, Orlandi E. Hadrontherapy for Thymic Epithelial Tumors: Implementation in Clinical Practice. Front Oncol 2021;11:738320. [PMID: 34707989 DOI: 10.3389/fonc.2021.738320] [Reference Citation Analysis]
10 Mercado CE, Hartsell WF, Simone CB, Tsai HK, Vargas CE, Zhu HJ, Henderson RH, Zeng J, Larson GL, Hoppe BS. Proton therapy for thymic malignancies: multi-institutional patterns-of-care and early clinical outcomes from the proton collaborative group and the university of Florida prospective registries. Acta Oncologica 2019;58:1036-40. [DOI: 10.1080/0284186x.2019.1575981] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
11 Choi JI, Khan AJ, Powell SN, McCormick B, Lozano AJ, Del Rosario G, Mamary J, Liu H, Fox P, Gillespie E, Braunstein LZ, Mah D, Cahlon O. Proton reirradiation for recurrent or new primary breast cancer in the setting of prior breast irradiation. Radiother Oncol 2021;165:142-51. [PMID: 34688807 DOI: 10.1016/j.radonc.2021.10.010] [Reference Citation Analysis]
12 Zhu HJ, Hoppe BS, Flampouri S, Louis D, Pirris J, Nichols RC, Henderson RH, Mercado CE. Rationale and early outcomes for the management of thymoma with proton therapy. Transl Lung Cancer Res. 2018;7:106-113. [PMID: 29876309 DOI: 10.21037/tlcr.2018.04.06] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
13 Thorpe CS, Niska JR, Brunnhoelzl DC, McGee LA, Kesslering CM, Hartsell WF, Vargas CE. First report of proton beam therapy for breast angiosarcoma from the prospective PCG registry. Acta Oncol 2018;57:992-4. [PMID: 29303019 DOI: 10.1080/0284186X.2017.1423179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Lideståhl A, Mondlane G, Gubanski M, Lind PA, Siegbahn A. An in silico planning study comparing doses and estimated risk of toxicity in 3D-CRT, IMRT and proton beam therapy of patients with thymic tumours. Physica Medica 2019;60:120-6. [DOI: 10.1016/j.ejmp.2019.03.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
15 Franceschini D, Cozzi L, Loi M, Franzese C, Reggiori G, Mancosu P, Clivio A, Fogliata A, Scorsetti M. Volumetric modulated arc therapy vs intensity-modulated proton therapy in the postoperative irradiation of thymoma. J Cancer Res Clin Oncol. 2020;146:2267-2276. [PMID: 32514629 DOI: 10.1007/s00432-020-03281-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
16 Lazarev S, Rosenzweig K, Samstein R, Salgado LR, Hasan S, Press RH, Sharma S, Powell CA, Hirsch FR, Simone CB 2nd. Where are we with proton beam therapy for thoracic malignancies? Current status and future perspectives. Lung Cancer 2021;152:157-64. [PMID: 33421922 DOI: 10.1016/j.lungcan.2020.12.025] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Rice SR, Li YR, Busch TM, Kim MM, McNulty S, Dimofte A, Zhu TC, Cengel KA, Simone CB 2nd. A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma. Photochem Photobiol. 2019;95:411-418. [PMID: 30485442 DOI: 10.1111/php.13065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
18 Jain V, Irmen P, O'Reilly S, Vogel JH, Lin L, Lin A. Predicted Secondary Malignancies following Proton versus Photon Radiation for Oropharyngeal Cancers. Int J Part Ther 2020;6:1-10. [PMID: 32582814 DOI: 10.14338/IJPT-19-00076.1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Ryckman JM, Ganesan V, Kusi Appiah A, Zhang C, Verma V. National practice patterns of proton versus photon therapy in the treatment of adult patients with primary brain tumors in the United States. Acta Oncol 2019;58:66-73. [PMID: 30280620 DOI: 10.1080/0284186X.2018.1512755] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]